pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Delstrigo
drug
save

(doravirine + lamivudine + tenofovir disoproxil fumarate)

Marketedupdated 3mo ago
by Merck Sharp & Dohme Corp (Inactive)
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval14 co-mentions · 7 sources
  • drugDELSTRIGO14 co-mentions · 7 sources
  • drugdoravirine7 co-mentions · 7 sources
  • tagSmall Molecule7 co-mentions · 7 sources
  • drugPIFELTRO7 co-mentions · 7 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

all catalysts(7)

approval · 7
Aug 30, 2018
approval
$MRK135.84+0.21%
8y ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Sep 19, 2019
approval
$MRK135.84+0.21%
7y ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Oct 10, 2019
approval
$MRK135.84+0.21%
7y ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Jan 27, 2022
approval
$MRK135.84+0.21%
5y ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Nov 7, 2024
approval
$MRK135.84+0.21%
2y ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Jun 12, 2025
approval
$MRK135.84+0.21%
1y ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→
Oct 29, 2025
approval
$MRK135.84+0.21%
10mo ago
DELSTRIGO (DORAVIRINE) — FDA approval
(doravirine + lamivudine + tenofovir disoproxil fumarate)
→

Trials studying (doravirine + lamivudine + tenofovir disoproxil fumarate)

  • phase2DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)recruitingn=32
  • phase3A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapyactive not recruitingn=600
  • phase4The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patientsterminatedn=18

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 30, 2032
~6.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Nov 29, 2036formulationUS 10603282
  • Nov 29, 2036formulationUS 10842751
  • Aug 30, 2032compositionUS 8486975

News(0)

no news has mentioned this drug yet

brand
Delstrigo
generic
(doravirine + lamivudine + tenofovir disoproxil fumarate)
MOA
12.1 Mechanism of Action DELSTRIGO is a fixed-dose combination of the antiretroviral drugs doravirine, lamivudine, and TDF [see Microbiology (12.4) ].
indication
Human Immunodeficiency Virus (HIV) Infections (AIDS)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?